Clinical Trial Update: Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease [Phase 4]

View source ↗

Summary

The Phase 4 clinical trial investigating botulinum toxin type A (Botox) for levodopa-induced peak-dose dyskinesias in Parkinson's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Botox (OnabotulinumtoxinA)

Snippet

Sponsor: University of Cincinnati | Conditions: Parkinson Disease | Phase 4 | Status: TERMINATED